RTW Biotech notes further investment in investee Encoded Therapeutics
(Alliance News) - RTW Biotech Opportunities Ltd on Friday said there was an additional investment in the financing of private portfolio company Encoded Therapeutics.
The investor in the life sciences sector said the investment is in the USD275 million Series F financing of the clinical-stage biotechnology company, which is developing one-time precision genetic medicines for severe neurological disorders.
Encoded's lead programme is ETX101, a one-time gene therapy for patients with Dravet syndrome, a severe treatment-resistant childhood epilepsy for which no approved therapy addresses the underlying genetic cause, RTW Biotech said.
RTW Biotech said it first invested in Encoded's series D financing in June 2020, and has invested a further USD4.1 million as part of this financing. It added that as of July 31, Encoded represented 0.1% of its net asset value.
RTE Investments Chief Investment Officer Rod Wong said: "This is one of the largest private financings of a CNS gene therapy company in recent years and is a strong endorsement of Encoded's science. It also underscores the potential for further value realisation in RTW Bio's portfolio as key programmes mature toward the clinic and public markets."
RTW Biotech shares were 0.9% higher at USD2.38 each on Friday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Are TIPS ETFs the Best Way to Fight Inflation?
What’s Ahead for Stocks This Quarter—and Where to Invest
United States